Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy

Background-Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na+ current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro.